PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.\', \'School of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC.\', \'Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC.\', \'Faculty of Pharmacy, National Yang-Ming University, Taipei, Taiwan, ROC.\', \'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.\', \'School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.\', \'Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan, ROC.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1097/JCMA.0000000000000353
?:doi
?:hasPublicationType
?:journal
  • Journal of the Chinese Medical Association : JCMA
is ?:pmid of
?:pmid
?:pmid
  • 32433345
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all